Kontour Medical(SH:688314) Quan Jing Wang·2025-03-28 08:46Core Viewpoint - 康拓医疗 reported a revenue of 322 million yuan for 2024, marking a year-on-year growth of 17.06%, and a net profit of approximately 88.4 million yuan, also reflecting a growth of 17.07% [1][2] Group 1: Financial Performance - The company achieved a net profit of 88.4 million yuan, with a basic earnings per share of 1.09 yuan [1] - The revenue from core products in the neurosurgery field reached 278 million yuan, growing by 14.09%, accounting for 89.19% of the main business revenue [2] - The revenue from PEEK material products was 206 million yuan, with a year-on-year increase of 23.33%, representing 66.03% of the main business revenue [2] Group 2: Product Development and Market Strategy - 康拓医疗 is focusing on diversifying its product offerings in neurosurgery, thoracic surgery, oral surgery, and facial reconstruction to ensure stable growth [2][3] - The company launched innovative products such as the "4D bioactive plate" and a full PEEK material skull repair solution, enhancing its market position [3][4] - R&D investment reached 29.6 million yuan, a 67.69% increase, representing 9.19% of revenue, indicating a strong commitment to innovation [4] Group 3: Market Position and Future Outlook - 康拓医疗 holds 20 Class III implant medical device registrations, with a leading market share in PEEK material skull repair products [1][4] - The company aims to leverage the opportunities presented by regional procurement policies to increase the market penetration of PEEK products [5][6] - The annual compound growth rate of the skull repair business from 2020 to 2024 was 15.69%, surpassing the industry average [4]